Probable metabolic interaction of doxifluridine with phenytoin

Annals of Pharmacotherapy

Volumn 36, Issue 5, 2002, Pages 831-834

  Konishi, Hiroki ^a   Morita, Kunihiko ^a,b   Minouchi, Tokuzo ^a   Nakajima, Masayuki ^c   Matsuda, Masayuki ^c   Yamaji, Akira ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE HOSPITAL   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Doxifluridine; Phenytoin

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 2C; DOXIFLURIDINE; MEDROXYPROGESTERONE ACETATE; PHENYTOIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN METASTASIS; CASE REPORT; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG WITHDRAWAL; ENZYME REGULATION; FEMALE; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEIZURE;

ANTICONVULSANTS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; FLOXURIDINE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PHENYTOIN;

EID: 0036096959     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A354     Document Type: Article

References (32)

1. Predicting phenytoin dose - A revised nomogram
2. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy
3. Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients
4. Role of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite
5. Cytochrome P450 isozymes and antiepileptic drug interactions
6. Pharmacokinetic drug interactions with phenytoin (part 1)
7. Population pharmacokinetics of phenytoin from routine clinical data in Japan
8. Therapeutic drug monitoring - Antiepileptic drugs
9. A method for estimating the probability of adverse drug reactions
10. Metabolism and biological activity of 5′-deoxy-5-fluorouridine, a novel fluoropyrimidine
11. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors
12. Modulation of the pharmacokinetics of 5′-deoxy-5- fluorouridine and 5-fluorouracil in rats by oral co-administration of acyclothymidine
13. Acute phenytoin intoxication in association with 5-fluorouracil
14. Phenytoin and fluorouracil interaction
15. Acute phenytoin intoxication caused by drug interaction with an anti-tumor agent (tegafur)
16. Acute phenytoin intoxication associated with the antineoplastic agent UFT
17. Effects of 5-fluorouracil treatment on rat liver microsomal enzymes
18. Modulation of the expression of constitutive rat hepatic cytochrome P450 isozymes by 5-fluorouracil
19. Possible drug interaction between warfarin and combination of levamisole, and fluorouracil
20. Multisite mucous membrane bleeding due to a possible interaction between warfarin and 5-fluorouracil
21. Warfarin-5-FU interaction - A consecutive case series
22. An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature
23. Implications of cytochrome P4502C9 polymorphism on warfarin metabolism and dosing
24. Preliminary evaluation of progestins as inducers of cytochrome P450 3A4 activity in postmenopausal women
25. The effect of medroxyprogesterone acetate on the hepatic drug-metabolizing enzymes in normal and protein deficient female rats
26. Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate
27. Development of a substrate-activity based approach to identify the major human P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles
28. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-4502A6 in human liver microsomes in vitro
29. 5-FU concentrations in the blood and tumor tissue after 5′-DFUR or UFT administration in the patients with uterine cervical cancer
30. Development of fluoropyrimidine derivatives
31. Thymidylate synthetase - Substrate complex formation
32. Metabolism of 5-fluorouracil in cultured cells. Protection from 5-fluorouracil cytotoxicity by purines